NSCLC molecular portrait of the sample of Czech population and indications of targeted therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000179" target="_blank" >RIV/26475821:_____/13:#0000179 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

čeština

Název v původním jazyce

NSCLC molecular portrait of the sample of Czech population and indications of targeted therapy

Popis výsledku v původním jazyce

Czech Republic belongs to countries with high lung cancer incidence. In 2010 there were diagnosed in 4636 men (incidence 89.8/100 000) and in 1887 women (incidence 35.2). In the same year there were 3998 lung cancer deaths in men´s population (mortality77.5/100 000) and 1556 women´s population (mortality 29.0/100 000). 85% of the patients were diagnosed as advanced stages of disease (stage III and IV). Molecular therapy targeted on tumour driving mutations should improve quality of life, PFS and overalsurvival in NSCLC patients. While EGFR mutations are widely used as indicator of gefitinib and erlotinib for the first line treatment of advanced NSCLC, recently, translocation of EML-4 ALK and ROS 1 amplification, should serve as a guide for indicationof crizotinib. Some other genetic changes, like EGFR amplification, c-met amplification, PIK3CA1 mutations and K-ras mutations should serve as prognostic or predictive factors of targeted therapy actually or in near future.

Název v anglickém jazyce

NSCLC molecular portrait of the sample of Czech population and indications of targeted therapy

Popis výsledku anglicky

Poster presenting diagnostics and molecular therapy in lung cancer patients in Czech Republic. Czech Republic belongs to countries with high lung cancer incidence. In 2010 there were diagnosed in 4636 men (incidence 89.8/100 000) and in 1887 women (incidence 35.2). In the same year there were 3998 lung cancer deaths in men´s population (mortality 77.5/100 000) and 1556 women´s population (mortality 29.0/100 000). 85% of the patients were diagnosed as advanced stages of disease (stage III and IV). Molecular therapy targeted on tumour driving mutations should improve quality of life, PFS and overal survival in NSCLC patients. While EGFR mutations are widely used as indicator of gefitinib and erlotinib for the first line treatment of advanced NSCLC, recently, translocation of EML-4 ALK and ROS 1 amplification, should serve as a guide for indication of crizotinib. Some other genetic changes, like EGFR amplification, c-met amplification, PIK3CA1 mutations and K-ras mutations should serve as

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR9087" target="_blank" >NR9087: Využití molekulárních prediktorů pro optimální selekci cílené léčby nemalobuněčného karcinomu plic</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů